HRK inactivation associated with promoter methylation and LOH in prostate cancer

Prostate

Volumn 68, Issue 1, 2008, Pages 105-113

  Higuchi, Tomonori ^a   Nakamura, Mitsutoshi ^a   Shimada, Keiji ^a   Ishida, Eiwa ^a   Hirao, Kazuya ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; HRK; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIGOXIGENIN; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN; PROTEIN HRK; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHROMOSOME 12Q; COMPARATIVE STUDY; CONTROLLED STUDY; GENE MUTATION; GLEASON SCORE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; MUTATIONAL ANALYSIS; NICK END LABELING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN METHYLATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DNA METHYLATION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MALE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37449002884     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20600     Document Type: Article

References (25)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
2. Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathol Int 2005;55(9):531-539.
3. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: Modulation by epidermal growth factor receptor activity. Brain Pathol 2002; 12(1):12-20.
4. Debatin KM, Stahnke K, Fulda S. Apoptosis in hematological disorders. Semin Cancer Biol 2003;13(2):149-158.
5. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998;18(3B):1989-1998.
6. Vakkala M, Lahteenmaki K, Raunio H, Paakko P, Soini Y. Apoptosis during breast carcinoma progression. Clin Cancer Res 1999;5(2):319-324.
7. Shimada K, Nakamura M, Ishida E, Konishi N. Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 2006;21(4):415-422.
8. Inohara N, Ding L, Chen S, Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). Embo J 1997;16(7):1686-1694.
9. Wistuba II, Tang M, Maitra A, Alvarez H, Troncoso P, Pimentel F, Gazdar AF. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61(9):3795-3800.
10. Kim HS, Woo DK, Bae SI, Kim YI, Kim WH. Allelotype of the adenoma-carcinoma sequence of the stomach. Cancer Detect Prev 2001;25(3):237-244.
11. Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 2003;9(17):6410-6418.
12. Nakamura M, Ishida E, Shimada K, Nakase H, Sakaki T, Konishi N, Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas. Acta Neuropathol (Berl) 2005;110(4):402-410.
13. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kenndy BI. Murphy GP. AJCC cancer staging manual, 5th edition. American Joint Committee on Cancer. Philadelphia: JB Lippincott-Raven; 1997.
14. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23(3):273-279.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93(18):9821-9826.
16. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K, Heterogeneous methylation, deletion, patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002;160(4):1207-1214.
17. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59(4):798-802.
18. INK4a methylation and p53 mutational status. Cancer Res 2000;60(1):129-133.
19. Konishi N, Nakamura M, Ishida E, Shimada K, Mitsui E, Yoshikawa R, Yamamoto H, Tsujikawa K. High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res 2005;11(14):5090-5097.
20. Konishi N, Nakamura M, Kishi M, Ishida E, Shimada K, Matsuyoshi S, Nagai H, Emi M. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 2003;94(9):764-768.
21. Alirol E, Martinou JC. Mitochondria and cancer: Is there a morphological connection? Oncogene 2006;25(34):4706-4716.
22. Harris CA, Johnson EM Jr, BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 2001;276(41):37754-37760.
23. Sanz C, Horita M, Fernandez-Luna JL. Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells. Haematologica 2002;87(9):903-907.
24. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96(15):8681-8686.
25. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005;206(4):423-432.